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doi:10.1016/j.ejvs.2008.10.001Abstract Objectives: The Walking Impairment Questionnaire (WIQ) is a frequently used ques-
tionnaire to evaluate patients with intermittent claudication (IC). The aim of this study is to
validate the Dutch WIQ for the European situation using the metric system.
Design: Validation study.
Materials: After translation and cultural adaptation of the WIQ, 130 patients with IC
completed the Dutch WIQ, the RAND-36, and the EuroQol questionnaire. Walking distances
were determined by treadmill testing.
Methods: Correlations between the WIQ, the two quality of life questionnaires, and walking
distances were calculated to determine validity. Reliability and internal consistency were
determined using the intraclass correlation coefficient (ICC) and Cronbach’s alpha,
respectively.
Results: Significant correlations were found between the WIQ and the absolute claudication
distance (ACD) (0.52), EuroQol (0.33) and seven domains of the RAND-36. Testeretest reli-
ability expressed by the ICC was 0.89. The internal consistency determined by Cronbach’s
alpha was 0.92 for the total WIQ score. Furthermore, a lower WIQ score corresponds to
a shorter ACD.
Conclusions: This study shows that the Dutch version of the WIQ using the European metric
system is a valid, reliable and clinically relevant instrument for assessing walking impairment
in patients with intermittent claudication.
ª 2008 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.ink, MD, PhD, Atrium Medical Centre, PO box 4446, 6401 CX Heerlen, The Netherlands. Tel.: þ31
c.nl (J.A.W. Teijink).
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Peripheral arterial disease (PAD) is a common manifes-
tation of atherosclerosis affecting the abdominal aorta
and peripheral arteries. The classic symptom of symp-
tomatic PAD is intermittent claudication, which describes
pain in one or both calves that relieves in rest and starts
with walking. Intermittent claudication often results in an
impairment of walking ability which can interfere with
personal, social or occupational factors in daily life.
Usually, treadmill testing is performed to assess the
severity of walking impairment.1 However, treadmill
testing is time consuming, often not available and
inconvenient. For this reason, Regensteiner (1990)
developed the Walking Impairment Questionnaire (WIQ).2
The WIQ is a short, easy to fill out questionnaire and
evaluates the degree of walking impairment in patients
with intermittent claudication on three domains; walking
distance, walking speed and the ability to climb stairs.
These three domains represent common daily activities
that are frequently impaired in patients with symptom-
atic PAD and contribute to the degree of walking
impairment. The WIQ is validated in the English and
Spanish language in United States customary units
(distances expressed as feet).2e4 The goal of this study is
to determine if the culturally adapted WIQ to the Euro-
pean metric situation in the Dutch language is a valid
instrument for measuring walking impairment in patients
with intermittent claudication.
Materials and methods
Patients and study design
One hundred and thirty consecutive patients with symp-
tomatic PAD (according to Fontaine stage II) were included
from a vascular outpatient clinical setting. Inclusion
criteria were patients with a maximal walking distance
<750 m assessed by a treadmill test. Exclusion criteria were
patients unable to walk on a treadmill, patients with PAD
according to Fontaine stage I, III or IV, patients with severe
cardiopulmonary co morbidities (NYHA 3 or 4), patients
with other co morbidities limiting walking ability or
patients with insufficient knowledge of the Dutch language.
Informed consent was obtained and the study was approved
by the medical ethical committee of the Atrium Medical
Centre Parkstad.
The concurrent validity was determined by comparing
the WIQ with the walking distances defined as the abso-
lute claudication distance (ACD) and functional claudica-
tion distance (FCD). The ACD represents the maximal
possible walking distance. The FCD is defined as the
moment the patient prefers to stop and would stop
walking in daily life. A treadmill test with a constant
speed of 3.2 km/h, starting at 0% incline increasing 2%
every 2 minutes was performed to asses ACD and FCD.5 To
determine the construct validity patients were asked to
fill out the WIQ and two quality of life questionnaires
(RAND-36, EuroQol). For the testeretest reliability 30
patients filled out a second WIQ 2 days after filling out
the first one.WIQ
The WIQ is a short, easy to fill out disease specific question-
naire validated in patients with intermittent claudication.2e4
It contains three domains measuring three important factors
of walking impairment in symptomatic PAD patients; walking
distance, walking speed and the ability to walk stairs.
The WIQ was translated according to Beaton’s guidelines
for the process of translation and cross-cultural adaptation
of self-report measures.6 The WIQ was independently
translated into Dutch by two bilingual translators with the
Dutch mother tongue and then translated back by two
native English-speaking translators. Inconsistencies in
translation among translators were resolved by discussion.
Cultural adaptation was necessary since the American
WIQ investigates the walking distance domain with stan-
dard sized living blocks as reference for the distance of
300 feet (91.4 m). In Europe ‘‘standard’’ sized living blocks
are not a common phenomenon, which implicates an
impaired applicability of the directly translated WIQ
regarding the European situation. Furthermore, United
States customary units (feet) were translated into meters
of the metric system. The authors formed a review
committee which examined the translations and agreed on
a final version which was culturally applicable and reflected
the intent of the instrument.
For each domain separately, a sub score of the Likert
items was calculated with a Likert scale.7 The total WIQ
score was the mean of the three subscores.
RAND-36
The RAND-36 is more commonly known as the Short Form 36
(SF-36), which uses a slightly different scoring algorithm
than the SF-36.8 The RAND-36 is a multidimensional generic
quality of life questionnaire assessing change in health and
eight health domains: physical functioning, social func-
tioning, physical role impairment, emotional role impair-
ment, mental health, vitality, pain and general health
experience. The change in health is evaluated in a separate
question with standardised response choices. The scores
are summed up and transformed to a scale ranging from
0 to 100 for every domain separately. A higher score means
a better health condition. In our study a validated Dutch
RAND-36 was applied.9e11
EuroQol
The EuroQol is a short questionnaire containing five ques-
tions with three possible answers. Each question encloses
one quality of life dimension: mobility, self care, daily
activities (e.g. work, study, domestic and creative activi-
ties), pain or other complains and fear or depression. A
formula converts the quality of life description into a total
quality of life score which is based on judgements of the
total general population.12
Measurements methods
A test is useful when it measures what it is intended to
measure (validity) and when the results stay consistent
across repeated measurements over time (reliability).
Table 1 Baseline socio-demographic and clinical charac-
teristics of the study participants (nZ 130)
Analysed population
(nZ 130)
Age (years) e mean (SD) 64.5 (10.1)
Men e n (%) 82 (63)
Body mass index e mean (SD) 27.1 (4.6)
Current smokers e n (%) 78 (60)
Former smokers e n (%) 46 (35.4)
Never smoked e n (%) 6 (4.6)
Packyears e mean (SD) 38 (24.1)
Hypertension e n (%) 87 (66.9)
Diabetes mellitus e n (%) 33 (25.4)
Coronary heart disease e n (%) 28 (21.5)
Stroke or transient
ischaemic attack (TIA) e n (%)
18 (13.8)
Chronic obstructive
pulmonary disease e n (%)
34 (26.2)
Ankle brachial index
Median (IQR) 0.70 (0.57 e 0.83)
Mean (SD) 0.70 (0.18)
Peripheral vascular
intervention e n (%)
47 (36.2)
Percutaneous transluminal
angioplasty e n (%)
44 (33.8)
Bypass e n (%) 12 (9.2)
Thrombo endarteriectomy e n (%) 6 (4.6)
Total score WIQ e mean (SD) 0.43 (0.22)
Functional claudication distance
Median (IQR) 165 (110 e 230)
Mean (SD) 194.2 (123.3)
Absolute claudication distance
Median (IQR) 240 (160 e 360)
Mean (SD) 272.1 (151.3)
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consistency and testeretest reliability were calculated.
The internal consistency measures the degree of homoge-
neity of a scale based on the correlation between each of
the items and the correlation between the items and the
total score. The testeretest reliability is estimated by
performing the questionnaire twice. The correlation
between the two questionnaires is used as a quantitative
measure. In this study the patient was asked to fill out
a second WIQ 2 days separated from the first WIQ; a period
long enough not to remember the exact answers from the
first time and short enough not to expect a therapy
effect.13
Validity was determined by measuring the concurrent
and construct validity. Concurrent validity measures the
extent to which a new test correlates with a golden
standard measuring the same construct, walking impair-
ment. In this study, the correlation between the WIQ and
the ACD and FCD assessed by a treadmill test were
calculated.
The construct validity is determined if a golden stan-
dard is absent and compares the WIQ with other tests
measuring the same construct. We compared the WIQ
with two quality of life questionnaires, the RAND-36 and
EuroQol, measuring the same construct, walking
impairment.
Statistical evaluation
Walking distances and the ankle brachial index (ABI) were
presented as median and inter-quartile-range (IQR) since
they were not normally distributed. Means are reported to
enable the comparison of results of this study with results
known from the literature. The internal consistency was
measured by calculating the Cronbach’s alpha. A widely
accepted cut-off is set between 0.7 and 0.9 for a set of
items to be considered a scale.14 Testeretest reliability was
assessed by the intraclass correlation coefficient (ICC) of
absolute agreement based on a two way mixed model with
95% confidence interval (CI).15
Correlations between the WIQ, the two quality of life
questionnaires and treadmill walking distances were
determined using Spearman correlation coefficients.
Statistical analysis was performed with SPSS version 15.0
for windows.Figure 1 (a) The total WIQ score plotted against the absolute cla
ankle brachial index.Results
Study population
One hundred and thirty patients with symptomatic PAD
were included in this study with a mean age of 64.5 (SD
10.1). Sixty-three percent of the patients included wereudication distance. (b) The total WIQ score plotted against the
Table 2 Testeretest reliability (nZ 30)
WIQ Baseline
mean (SD)
Retest
mean (SD)
Change of scores
mean (SD)
Testeretest
(intraclass correlation
coefficient)
95% confidence
interval
Distance 0.35 (0.26) 0.37 (0.25) 0.01 (0.18) 0.785 0.56e0.90
Speed 0.39 (0.22) 0.47 (0.25) 0.04 (0.15) 0.797 0.60e0.91
Stair climbing 0.54 (0.31) 0.53 (0.27) 0.06 (0.19) 0.751 0.51e0.88
Total score 0.43 (0.22) 0.44 (0.22) 0.03 (0.11) 0.890 0.76e0.95
Validation Dutch WIQ 59male. Forty-four (33.8%) patients underwent a percuta-
neous transluminal angioplasty (PTA), 12 (9.2%) patients
received a bypass and six (4.6%) patients had a thrombo
endarteriectomy (TEA), previously. While several patients
underwent more than one vascular intervention, a total of
47 (36.2%) patients had (multiple) peripheral arterial
surgery in their history. The median lowest ABI was 0.70
(IQR 0.57e 0.83) and the median FCD and ACD were 165 m
(IQR 110e 230) and 240 m (IQR 160e 360) , respectively.
The mean total score of the WIQ was 0.43 (SD 0.22). Other
baseline socio-demographic and clinical characteristics of
the patients are shown in Table 1. In Fig. 1a,b the total WIQ
scores of the individual patients are plotted against the ACD
and the ABI, respectively.
Internal consistency and reliability
At baseline all patients filled out the WIQ with a mean total
score of 0.43 (SD 0.22). The internal consistency was 0.91
for the distance domain, 0.81 for the speed domain, 0.86
for the stair climbing domain, and 0.92 for the total WIQ
score. This implicates a sufficient homogeneity of all the
individual domains as well as the total questionnaire. Thirty
patients completed the WIQ at baseline and 2 days later to
determine the testeretest reliability expressed by the ICC.
For the individual WIQ domains the ICC varies between 0.75
and 0.80, the ICC of the total WIQ score was highest (0.89)
indicating a good testeretest reliability. Table 2 summa-
rizes these results.
Validity
The concurrent validity as determined by the correlation
between the WIQ and the FCD and ACD showed a fairly
strong association. The correlation coefficients were 0.52
for the total WIQ score compared with the ACD and 0.48
between the WIQ and the FCD. Correlation coefficients for
all WIQ domains are presented in Table 3.Table 3 Concurrent validity; Spearman correlation coef-
ficients between WIQ, functional claudication distance and
absolute claudication distance with p-values (nZ 130)
WIQ Functional
claudication
distance
Absolute
claudication
distance
Distance 0.43 (<0.01) 0.45 (<0.01)
Speed 0.45 (<0.01) 0.43 (<0.01)
Stair climbing 0.32 (<0.01) 0.37 (<0.01)
Total score 0.48 (<0.01) 0.52 (<0.01)The walking distances in relation to the total WIQ scores
divided into tertiles are given in Table 4. Lower scores of
the WIQ correspond with shorter walking distances and
higher scores with longer walking distances.
The construct validity based on the correlation between
the WIQ and other questionnaires measuring the same
construct, showed highest Spearman correlation coeffi-
cients between the WIQ and the RAND-36 for the subscales
physical functioning (rho 0.70) and pain (rho 0.35). Corre-
lation coefficients between the WIQ and the EuroQol varied
between 0.26 and 0.33. Table 5 presents a detailed over-
view of the correlations of all WIQ domains, RAND-36 and
EuroQol.
Discussion
Our results demonstrate that the Dutch version of the WIQ,
using the European metric system, is an internally consis-
tent, reliable and valid questionnaire for the evaluation of
walking impairment in patients with intermittent claudi-
cation. This implies that the Dutch WIQ can easily (with the
forwardebackward method according to Beaton) be trans-
lated for other European countries without further need for
cultural adaptation.
By comparing our results with the literature we found
that none of the prior studies calculated a total WIQ score,
which means there are no directly comparable results
available. For the concurrent validity (total WIQ score
compared with treadmill testing), we found a correlation
coefficient of 0.52 for the ACD. Regensteiner et al. devel-
oped and validated the WIQ in the English language in
a small population of 26 patients and reported a significant
correlation of 0.68 between the distance domain of the WIQ
and the ACD.2 Quantitative measures (ABI, ACD and self-
selected treadmill pace) were compared with qualitative
measures (WIQ and SF-36) by Myers et al.16 Correlations of
0.43, 0.41 and 0.39 were reported for the WIQ distance,
speed and climbing the stairs domains, respectively inTable 4 Tertiles of the WIQ compared with the mean
functional claudication distance and absolute claudication
distance (nZ 130)
WIQ total
score in
tertiles
Functional
claudication
distance (m) e
mean (SD)
Absolute
claudication
distance (m) e
mean (SD)
0.00 e 0.33 128.7 (65.3) 178.9 (81.9)
0.34 e 0.51 198.1 (106.7) 295.0 (133.2)
0.52 e 0.96 263.4 (161.3) 351.9 (181.0)
Table 5 Construct validity; Spearman correlation coefficients between WIQ, EuroQol and RAND with p-values (nZ 130)
WIQ distance WIQ speed WIQ stairs Total
RAND-36
Functional status Physical functioning 0.513 (<0.01) 0.557 (<0.01) 0.615 (<0.01) 0.697 (<0.01)
Social functioning 0.091 (0.32) 0.144 (0.11) 0.117 (0.19) 0.108 (0.25)
Role impairment (physical) 0.228 (0.01) 0.281 (<0.01) 0.244 (<0.01) 0.273 (<0.01)
Role impairment (emotional) 0.140 (0.13) 0.210 (0.02) 0.187 (0.04) 0.197 (0.03)
Welbeing Mental health 0.188 (0.04) 0.191 (0.04) 0.159 (0.08) 0.184 (0.05)
Vitality 0.202 (0.03) 0.222 (0.02) 0.241 (<0.01) 0.251 (<0.01)
Pain 0.338 (<0.01) 0.351 (<0.01) 0.267 (<0.01) 0.352 (<0.01)
General evaluation General health experience 0.262 (<0.01) 0.215 (0.02) 0.169 (0.06) 0.267 (<0.01)
Health Change in health 0.165 (0.07) 0.143 (0.12) 0.207 (0.02) 0.181 (0.05)
EuroQol 0.324 (<0.01) 0.287 (<0.01) 0.256 (<0.01) 0.328 (<0.01)
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dated in a heterogeneous group of patients with and
without PAD and correlations of 0.56 between the WIQ
distance score and the 6-minute walk score, and correla-
tions of 0.53 between the WIQ speed score and the 4 min
usual pace score were reported.3 A possible explanation
for the slightly lower correlation coefficients found in our
study in comparison with Regensteiner et al.2 could be the
cultural adaptation in which ‘‘American feet’’ were trans-
lated into meters and where ‘‘standard size living blocks’’,
which are not a common phenomenon in Europe, could not
be incorporated into the Dutch questionnaire as a refer-
ence for the distance.
A limitation of our study is the fact that the WIQ was
compared with walking distance as measured on a treadmill
and not with the actual walking distance of a patient in
daily life. Although treadmill testing has face validity for
walking ability, great variation between the subjective
walking distance and the walking distance as measured on
a treadmill17,18 has been demonstrated. Hence, the real
golden standard for determining the concurrent validity
would be a test with a patient walking on the street.
However, the American College of Sports Medicine recom-
mend to evaluate PAD patients with a graded or a gradual
ramp protocol on a treadmill.1 In our study we partially
covered this problem by additionally measuring the
construct validity.
The correlation coefficients representing the construct
validity between the WIQ and the RAND-36 were 0.70 and
0.35 for the subscales physical functioning and pain,
respectively. The correlation between the total WIQ score
and the EuroQol was 0.33. We found comparable results for
the separate WIQ domains in the literature.4,16
Our study shows that the WIQ can be of use in properly
designed clinical trials evaluating therapy effect in PAD
patients and in an outpatient clinical setting to evaluate
the degree of walking impairment. This is demonstrated
by dividing total WIQ scores into tertiles, where lower
scores of the WIQ correspond with shorter walking
distances and higher scores with longer walking
distances. This implies that the WIQ gives an impression
of functional capacity. It would be interesting to know if
the Dutch WIQ is able to detect the effect of conservative
or invasive therapy.We conclude that the Dutch version of the WIQ using the
European metric system is a valid and reliable instrument
for assessing walking impairment in patients with
intermittent claudication.
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